Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation

World Journal of Gastroenterology

Volumn 13, Issue 30, 2007, Pages 4149-4151

  Ichikawa, Tatsuki ^a   Nakao, Kazuhiko ^a   Hamasaki, Kelsuke ^a   Honda, Takuya ^a   Shibata, Hidetaka ^a   Akahoshi, Mana ^a   Eguchi, Susumu ^a   Takatsuki, Mitsuhisa ^a   Kanematsu, Takashi ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus; Liver transplantation; Pegylated interferon

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; BILIRUBIN; HEPATITIS C ANTIGEN; PEGINTERFERON ALPHA2A; PREDNISOLONE; STEROID; TACROLIMUS; VIRUS RNA;

ADULT; ANASTOMOSIS; ARTERY INJURY; ARTICLE; ARTIFICIAL VENTILATION; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHEMOEMBOLIZATION; COMMON BILE DUCT STENOSIS; DEPRESSION; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; HEMATOMA; HEPATIC ARTERY; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERBARIC OXYGEN; INFECTION; LAPAROTOMY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMONIA; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; TRACHEOSTOMY; VEIN THROMBOSIS; VIREMIA;

EID: 34548294168     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i30.4149     Document Type: Article

References (16)

1. Takada Y, Ueda M, Ito T, Sakamoto S, Haga H, Maetani Y, Ogawa K, Kasahara M, Oike F, Egawa H, Tanaka K. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 2006; 12: 912-919
2. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684
3. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl 2003; 9: S95-S100
4. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics dunng and immediately after liver transplantation. Hepatology 2002, 35: 680-687
5. Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, Conrad AJ, McHutchison J, Perelson AS. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006; 12: 207-216
6. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124
7. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antivir Ther 2004; 9: 491-497
8. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, Martin P, Teperman L, Jiao J, Lopez-Talavera JC. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-298
9. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-855
10. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-915
11. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, Garcia-Valdecasas JC, Navasa M, Rimola A, Rodes J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396
12. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262
13. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, van der Laan LJ. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006; 131: 1452-1462
14. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004: 10: 199-207
15. Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, Souquet JC, Ducerf C, Baulieux J, Zoulim F, Trepo, C. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 1909-1913
16. Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, Guichard S, Ducerf C, Baulieux J, Zoulim F, Trepo C. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283-287